Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
| Autor: | Peter Compton, Ivor Caro, Steven R. Feldman, Kim A. Papp, Alice B. Gottlieb, Alan Menter, Patricia A. Walicke, Craig L. Leonardi, Kenneth B. Gordon |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Randomization medicine.medical_treatment Efalizumab Dermatology Antibodies Monoclonal Humanized Placebo Gastroenterology Double-Blind Method Psoriasis Area and Severity Index Psoriasis Internal medicine medicine Humans Immunologic Factors Aged Body surface area Chemotherapy Intention-to-treat analysis CD11 Antigens business.industry Antibodies Monoclonal Middle Aged medicine.disease Surgery Female Dermatologic Agents business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 52:425-433 |
| ISSN: | 0190-9622 |
| Popis: | Efalizumab inhibits multiple T-cell-mediated processes.To evaluate 12- and 24-week efalizumab therapy for psoriasis.In this phase III, randomized, double-blind trial, 498 patients received subcutaneous 1 or 2 mg/kg/wk efalizumab or placebo for 12 weeks. Efalizumab-treated patients who achieved75% Psoriasis Area and Severity Index improvement (PASI-75) were re-randomized to a second 12-week course of treatment. Results At week 12, 39% and 27% of efalizumab-treated patients (1 and 2 mg/kg, respectively) achieved PASI-75 (vs 2% placebo; P.001, both dose groups). At week 24, an additional 20% of efalizumab-treated patients achieved PASI-75 (vs placebo 7%, P = .018). Efalizumab was well tolerated.Twelve-week efalizumab treatment resulted in significant improvement; extension of therapy to 24 weeks resulted in additional improvement in patients who initially had not achieved PASI-75. There were no significant changes in safety profile during weeks 13-24. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect